Table 2. Treatment given to patients with confirmed Ebola virus disease admitted to the treatment center in Moyamba District, Sierra Leone, December 19, 2014–February 17, 2015*.
| Treatment | No. (%) patients |
OR (95% CI) | p value† | ||
|---|---|---|---|---|---|
| Total, N = 31 | Died, N = 18 | Survived, N = 13 | |||
| Intravenous fluids | 26 (84) | 17 (94) | 9 (69) | 7.6 (0.90–97.0) | 0.096 |
| Antimalarial drugs | 29 (94) | 17 (94) | 12 (92) | 1.4 (0.07–28.0) | 0.748 |
| Ceftriaxone | 23 (74) | 14 (78) | 9 (69) | 1.6 (0.37–6.4) | 0.551 |
| Metronidazol | 13. (42) | 8 (44) | 5 (38) | 1.3 (0.33–5.8) | 0.864 |
| Albendazol | 5 (16) | 1 (6) | 4 (31) | 0.1 (0.01–1.1) | 0.096 |
| Zinc | 29 (94) | 17 (94) | 12 (92) | 1.4 (0.07–28.0) | 0.748 |
*OR, odds ratio. †p values calculated by the Fisher 2-tailed exact mid-p test.